Response to "What is the Current Clinical Impact of the CYP2C:TG Haplotype?"

被引：0
|
作者：
Zubiaur, Pablo [1 ]
Leeder, J. Steven [2 ,3 ]
Abad-Santos, Francisco [1 ,4 ]
Gaedigk, Andrea [2 ,3 ]
机构：
[1] Univ Autonoma Madrid UAM, Inst Invest Sanitaria Princesa IP, Inst Teofilo Hernando, Clin Pharmacol Dept,Hosp Univ La Princesa, Madrid, Spain
[2] Childrens Mercy Res Inst CMRI, Div Clin Pharmacol Toxicol & Therapeut Innovat, Kansas City, MO 64108 USA
[3] Univ Missouri Kansas City, Sch Med, Kansas City, MO 64110 USA
[4] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2024年 / 115卷 / 02期
关键词：
D O I：
10.1002/cpt.3093
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：184 / 184
页数：1
相关论文
共 50 条
  • [21] CYP2C44, a new murine CYP2C that metabolizes arachidonic acid
    DeLozier, TC
    Tsao, CC
    Coulter, SJ
    Zeldin, DC
    Goldstein, JA
    DRUG METABOLISM REVIEWS, 2003, 35 : 104 - 104
  • [22] Molecular modelling of human CYP2C subfamily enzymes CYP2C9 and CYP2C19: rationalization of substrate specificity and site-directed mutagenesis experiments in the CYP2C subfamily
    Lewis, DFV
    Dickins, M
    Weaver, RJ
    Eddershaw, PJ
    Goldfarb, PS
    Tarbit, MH
    XENOBIOTICA, 1998, 28 (03) : 235 - 268
  • [23] Functional impact of CYP2C*5, CYP2C9*6, CYP2C9*8, and CYP2C9*11 in vivo among black Africans
    Allabi, AC
    Gala, JL
    Horsmans, Y
    Babaoglu, MO
    Bozkurt, A
    Heusterspreute, M
    Yasar, U
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (02) : 113 - 118
  • [24] EVOLUTION OF CYP2C GENE CLUSTER AMONG THE HOMINOIDEA
    Chaney, M. E.
    Tosi, A. J.
    Piontkivska, H.
    AMERICAN JOURNAL OF PRIMATOLOGY, 2018, 80
  • [25] Effect of chlorinated ethylenes on the expression of rat CYP2C
    Nakahama, T
    Mizuno, M
    Sekiguchi, M
    Sakamaki, H
    Inouye, Y
    JOURNAL OF HEALTH SCIENCE, 2002, 48 (06) : 514 - 519
  • [26] Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes
    Laimonas Griskevicius
    Ümit Yasar
    Mia Sandberg
    Mats Hidestrand
    Erik Eliasson
    Gunnel Tybring
    Moustapha Hassan
    Marja-Liisa Dahl
    European Journal of Clinical Pharmacology, 2003, 59 : 103 - 109
  • [27] Bioactivation of cyclophosphamide:: the role of polymorphic CYP2C enzymes
    Griskevicius, L
    Yasar, Ü
    Sandberg, M
    Hidestrand, M
    Eliasson, E
    Tybring, G
    Hassan, M
    Dahl, ML
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 59 (02) : 103 - 109
  • [28] CYP2C gene polymorphisms in North African populations
    Messaoudi, Mohsen
    Pakstis, Andrew J.
    Boussetta, Sami
    Ben Ammar Elgaaied, Amel
    Kidd, Kenneth K.
    Cherni, Lotfi
    MOLECULAR BIOLOGY REPORTS, 2024, 51 (01)
  • [29] Distribution of CYP2C Polymorphisms in an Amerindian Population of Brazil
    Vargens, Daniela D.
    Petzl-Erler, Maria-Luiza
    Suarez-Kurtz, Guilherme
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2012, 110 (04) : 396 - 400
  • [30] Clinically Significant CYP2C Inhibition by Noscapine but Not by Glucosamine
    Rosenborg, S.
    Stenberg, M.
    Otto, S.
    Ostervall, J.
    Masquelier, M.
    Yue, Q-Y
    Bertilsson, L.
    Eliasson, E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (03) : 343 - 346
12345